Endocrinology
From the Journals
Air pollution seen acting on stress hormones
A novel study in China identifies several potential pathways between exposure and increased cardiovascular and metabolic disease risk.
Feature
Award for best hospital goes to … the Mayo Clinic
The U.S. News Best Hospitals Honor Roll for 2017-2018 includes the usual suspects, with the University of Michigan making a big move up the list...
Conference Coverage
Thyroid-nodule size boosts serum thyroglobulin’s diagnostic value
Size does matter – at least when it comes to normalizing the serum thyroglobulin level.
Conference Coverage
VIDEO: Less follow-up proposed for low-risk thyroid cancer
BOSTON – Can some patients with good treatment responses safely transition to follow-up monitoring at longer intervals?
Conference Coverage
Is that thyroid nodule malignant?
ESTES PARK, COLO. – Here’s a guideline-backed evaluation strategy for sorting out malignant from benign thyroid nodules.
News from the FDA/CDC
Over 45% of American adults have type 2 diabetes mellitus or prediabetes
CDC: Most people with prediabetes don’t know they have it.
From the Journals
Surgeon, primary care collaboration needed to catch hyperparathyroidism
Of 10,432 patients identified with hypercalcemia at the University of Alabama at Birmingham from 2011 to 2015, only 3,200 patients (31%) had a...
Conference Coverage
Anabolic agents for osteoporosis have limited role so far
Parathyroid hormone and parathyroid hormone-related protein analogs show promise for osteoporosis, but, for now, they’re reserved for the most...
Conference Coverage
Meta-analysis: Bisphosphonates mitigate glucocorticoid-induced bone loss
MADRID – The drugs examined were ibandronate, alendronate, risedronate, etidronate, and clodronate.
Guidance for Practicing Primary Care
Treatment of low bone density or osteoporosis to prevent fractures in men and women
This guideline update focuses on treatment with bisphosphonates (alendronate, risedronate, ibandronate, zoledronic acid) and denosumab.
Conference Coverage
Romosozumab cuts new vertebral fracture risk by 73%, but safety data are concerning
MADRID – Investigational bone-building drug looks promising, but safety concerns emerge.